A phase II trial of cisplatin and interferon alpha 2b in patients with advanced bladder cancer.
Date
1997
Authors
Parnis, F.
Olver, I.
Sandeman, T.
Bishop, J.
Laidlaw, C.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
American Journal of Clinical Oncology: Cancer Clinical Trials, 1997; 20(3):319-321
Statement of Responsibility
Conference Name
Abstract
Twenty-two patients with advanced transitional cell bladder cancer were treated in a phase II trial exploring the possible synergy of cisplatin and interferon alpha 2b. Of the 20 evaluable patients, 7 (35%) had a partial response to the treatment, and only 6 patients were able to complete the full planned six cycles of treatment. Response rates, duration of responses, and overall survival of our patients are not superior to those expected by cisplatin alone.